Last reviewed · How we verify
POTASSIUM HYDROXIDE
Potassium Hydroxide is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent expiry presents a significant competitive advantage by protecting its composition until 2028. The primary risk is the potential increase in competition post-2028, which could impact market share and revenue.
At a glance
| Generic name | POTASSIUM HYDROXIDE |
|---|---|
| Drug class | Anticholinergic [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis (PHASE3)
- Point-of-care Tests for Vaginal Discharge in Nepal (NA)
- Multimodal Morpho-functional Study in Glaucoma Patients-Citicoline Oral Solution (NA)
- Hepatitis B Vaccine Delivered Trans-dermally by MAP (PHASE1)
- Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
- Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke (PHASE4)
- Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants (PHASE3)
- 5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- POTASSIUM HYDROXIDE CI brief — competitive landscape report
- POTASSIUM HYDROXIDE updates RSS · CI watch RSS